BAY 1161116
Alternative Names: BAY-1161116Latest Information Update: 28 May 2020
Price :
$50 *
At a glance
- Originator Bayer
- Class Antiandrogens; Infertility therapies
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Polycystic ovary syndrome
Most Recent Events
- 28 May 2020 No recent reports of development identified for phase-I development in Polycystic-ovary-syndrome(In volunteers) in Germany (PO)
- 31 Jan 2018 Bayer discontinued phase-I clinical trials in Polycystic ovary syndrome (In volunteers) in Germany (NCT03119077)
- 27 Apr 2017 Phase-I clinical trials in Polycystic ovary syndrome (In volunteers) in Germany (NCT03119077)